Comparison of reporting rates of arthritis and arthralgia following AstraZeneca, Pfizer-BioNTech, Moderna, and Janssen vaccine administration against SARS-CoV-2 in 2021: analysis of European pharmacovigilance large-scale data.
Adverse drug reactions
Arthralgia
Arthritis
EudraVigilance
SARS-CoV-2 vaccination
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
24 Dec 2023
24 Dec 2023
Historique:
received:
15
10
2023
accepted:
23
11
2023
medline:
24
12
2023
pubmed:
24
12
2023
entrez:
24
12
2023
Statut:
aheadofprint
Résumé
This study aimed to investigate the reporting rates of arthritis and arthralgia following the administration of four vaccines against SARS-CoV-2: Pfizer-BioNTech (Tozinameran), Moderna (CX-024414), AstraZeneca (Chadox1 NCOV-19), and Janssen (AD26.COV2.S) in 2021. We used data from the EudraVigilance database, specifically analyzing spontaneous reports of suspected adverse reactions (ADRs) from the European Union (EU)/European Economic Area (EEA) region. Age-group-specific reporting rates were calculated by dividing the number of arthralgia and arthritis reports per 1,000,000 vaccine doses administered per age group. Reporting rates were compared using a rate ratio among the four vaccines, using the AstraZeneca vaccine as a comparator. The AstraZeneca vaccine was associated with the highest rate of arthralgia across all age groups. Arthritis reporting rates were significantly lower, with the AstraZeneca vaccine having the highest rates in most age groups, except the 60-69 and 80+ groups, where the Janssen and Pfizer-BioNTech vaccines demonstrated higher reporting rates, respectively. The distribution of arthritis rates did not follow the arthralgia pattern, being higher in the 50-79 age group. This study is the first spontaneous reporting system analysis of arthritis reporting rates post-SARS-CoV-2 vaccination at a European level, revealing a higher reporting of suspected musculoskeletal adverse reactions after AstraZeneca vaccination. The findings underscore the need to consider commonly reported events like arthralgia in risk-benefit assessments prior to vaccination against SARS-CoV-2. Given the high prevalence of rheumatic and musculoskeletal diseases and vaccine hesitancy in this population, our results could influence vaccine choice and acceptance.
Identifiants
pubmed: 38142450
doi: 10.1007/s00296-023-05512-1
pii: 10.1007/s00296-023-05512-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Guimarães LE, Baker B, Perricone C, Shoenfeld Y (2015) Vaccines, adjuvants and autoimmunity. Pharmacol Res 100:190–209. https://doi.org/10.1016/j.phrs.2015.08.003
doi: 10.1016/j.phrs.2015.08.003
pubmed: 26275795
pmcid: 7129276
Cross JW, Joy M, McGee C, Akinyemi O, Gatenby P, de Lusignan S (2020) Adverse events of interest vary by influenza vaccine type and brand: sentinel network study of eight seasons (2010–2018). Vaccine 38:3869–3880. https://doi.org/10.1016/j.vaccine.2020.03.034
doi: 10.1016/j.vaccine.2020.03.034
pubmed: 32299719
Centers for Disease Control and Prevention (2023) Seasonal Flu Vaccines. Centers for Disease Control and Prevention. https://www.cdc.gov/flu/prevent/flushot.htm . Accessed 31 May 2023
European Centre for Disease Prevention and Control (2023) COVID-19 Vaccine Tracker. European Centre for Disease Prevention and Control – An agency of the European Union. https://www.ecdc.europa.eu/en/publications-data/covid-19-vaccine-tracker . Accessed 8 Jan 2023
Cari L, Fiore P, Naghavi Alhosseini M, Sava G, Nocentini G (2021) Blood clots and bleeding events following BNT162b2 and ChAdOx1 nCoV-19 vaccine: an analysis of European data. J Autoimmun 122:102685. https://doi.org/10.1016/j.jaut.2021.102685
doi: 10.1016/j.jaut.2021.102685
pubmed: 34174723
pmcid: 8220408
Driedger MS, Capurro G, Tustin J, Jardine CG (2023) “I won’t be a guineapig”: Rethinking public health communication and vaccine hesitancy in the context of COVID-19. Vaccine 41:1–4. https://doi.org/10.1016/j.vaccine.2022.11.056
doi: 10.1016/j.vaccine.2022.11.056
Medical Dictionary for Regulatory Activities (2021) MedDRA Version 24.1 September 2021. Medical Dictionary for Regulatory Activities. https://www.meddra.org/how-to-use/support-documentation/english/welcome . Accessed 19 March 2023
European Centre for Disease Prevention and Control (2022). Data on COVID-19 Vaccination in the EU/EEA. European Centre for Disease Prevention and Control – An agency of the European Union. https://www.ecdc.europa.eu/en/publications-data/data-covid-19-vaccination-eu-eea . Accessed 15 Aug 2022
Klok FA, Pai M, Huisman MV, Makris M (2022) Vaccine-induced immune thrombotic thrombocytopenia. Lancet Haematol 9:73–80. https://doi.org/10.1016/S2352-3026(21)00306-9
doi: 10.1016/S2352-3026(21)00306-9
Medicines and Healthcare Products Regulatory Agency (2023). Coronavirus Vaccines – Summary of Yellow Card Reporting - Data included 9/12/2020 to 20/4/2022. Medicines and Healthcare Products Regulatory Agency. https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting . Accessed 5 Apr 2023
Montano D (2022) Frequency and associations of adverse reactions of COVID-19 vaccines reported to pharmacovigilance systems in the European union and the United States. Front Public Health 9:756633. https://doi.org/10.3389/fpubh.2021.756633
doi: 10.3389/fpubh.2021.756633
pubmed: 35186864
pmcid: 8850379
Prontskus V, Fresse A, Yelehe-Okouma M, Facile A, Pietri T, Simon C, Le Souder C, Beurrier M, Gillet P, French network of Regional Pharmacovigilance Centres (2023) COVID-19 vaccination and the incidence of De Novo or recurrent rheumatoid arthritis: a French and international (VigiBase) signal detection study. Clin Pharmacol Ther 113:1107–1116. https://doi.org/10.1002/cpt.2866
doi: 10.1002/cpt.2866
pubmed: 36752604
Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Ménard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovský J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581. https://doi.org/10.1002/art.27584
doi: 10.1002/art.27584
pubmed: 20872595
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, Hu C, Selvachandran S, Antonelli M, Murray B, Canas LS, Molteni E, Graham MS, Modat M, Joshi AD, Mangino M, Hammers A, Goodman AL, Chan AT, Wolf J, Steves CJ, Valdes AM, Ourselin S, Spector TD (2021) Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis 21:939–949. https://doi.org/10.1016/S1473-3099(21)00224-3
doi: 10.1016/S1473-3099(21)00224-3
pubmed: 33930320
pmcid: 8078878
Anastassopoulou C, Hatziantoniou S, Vlachopoulos C, Spanakis N, Tsioufis C, Tsakris A, Lazaros G (2022) Temporal relationship of myocarditis and pericarditis following COVID-19 vaccination: a pragmatic approach. Int J Cardiol 358:136–139. https://doi.org/10.1016/j.ijcard.2022.04.024
doi: 10.1016/j.ijcard.2022.04.024
pubmed: 35436559
pmcid: 9011898
MacDonald NE, SAGE Working Group on Vaccine Hesitancy (2015) Vaccine hesitancy: definition, scope and determinants. Vaccine 33:4161–4164. https://doi.org/10.1016/j.vaccine.2015.04.036
doi: 10.1016/j.vaccine.2015.04.036
Priori R, Pellegrino G, Colafrancesco S, Alessandri C, Ceccarelli F, Di Franco M, Riccieri V, Scrivo R, Sili Scavalli A, Spinelli FR, Conti F (2021) SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists. Ann Rheum Dis 80:953–954. https://doi.org/10.1136/annrheumdis-2021-220059
doi: 10.1136/annrheumdis-2021-220059
pubmed: 33622689
Lazarus JV, Wyka K, White TM, Picchio CA, Rabin K, Ratzan SC, Parsons Leigh J, Hu J, El-Mohandes A (2022) Revisiting COVID-19 vaccine hesitancy around the world using data from 23 countries in 2021. Nat Commun 13:3801. https://doi.org/10.1038/s41467-022-31441-x
doi: 10.1038/s41467-022-31441-x
pubmed: 35778396
pmcid: 9247969
Gaur P, Agrawat H, Shukla A (2021) COVID-19 vaccine hesitancy in patients with systemic autoimmune rheumatic disease: an interview-based survey. Rheumatol Int 41:1601–1605. https://doi.org/10.1007/s00296-021-04938-9
doi: 10.1007/s00296-021-04938-9
pubmed: 34213580
pmcid: 8249840
Yurttas B, Poyraz BC, Sut N, Ozdede A, Oztas M, Uğurlu S, Tabak F, Hamuryudan V, Seyahi E (2021) Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey. Rheumatol Int 41:1105–1114. https://doi.org/10.1007/s00296-021-04841-3
doi: 10.1007/s00296-021-04841-3
pubmed: 33779780
pmcid: 8006103
Sen P, Roh N, Houshmand N, Moghadam Kia S, Joshi M, Saha S, Jagtap K, Agarwal V, Nune A, Nikiphorou E, Tan AL, Shinjo SK, Ziade N, Velikova T, Milchert M, Parodis I, Gracia-Ramos AE, Cavagna L, Kuwana M, Knitza J, Makol A, Patel A, Pauling JD, Wincup C, Barman B, Zamora Tehozol EA, Rojas Serrano J, García-De La Torre I, Colunga-Pedraza IJ, Merayo-Chalico J, Chibuzo OC, Katchamart W, Akawatcharangura Goo P, Shumnalieva R, Chen YM, Hoff LS, El Kibbi L, Halabi H, Vaidya B, Sazliyana Shaharir S, Hasan ATMT, Dey D, Gutiérrez CET, Caballero-Uribe CV, Lilleker JB, Salim B, Gheita T, Chatterjee T, Distler O, Saavedra MA, Day J, Chinoy H, COVAD Study Group, Agarwal V, Aggarwal R, Gupta L (2023) Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis: a comparative analysis of the COVAD surveys. Rheumatology (Oxford) 62:3291–3301. https://doi.org/10.1093/rheumatology/kead057
doi: 10.1093/rheumatology/kead057
pubmed: 36734536
Gastelum-Strozzi A, Flores-Alvarado DE, Pascual-Ramos V, Álvarez-Hernández E, Pacheco-Tena CF, Guaracha-Basáñez GA, García CG, González-Chávez SA, Moctezuma-Ríos JF, Manrique de Lara A, Esquivel-Valerio JA, Contreras-Yáñez I, Galarza-Delgado DÁ, Vázquez-Mellado J, Peláez-Ballestas I, Reyes-Cordero GC (2023) The COVID-19 epidemic curve and vaccine acceptance among patients with rheumatic diseases: an ecological study. Rheumatol Int 43:1253–1264. https://doi.org/10.1007/s00296-023-05334-1
doi: 10.1007/s00296-023-05334-1
pubmed: 37129609
pmcid: 10153056
Paik JJ, Sparks JA, Kim AHJ (2022) Immunogenicity, breakthrough infection, and underlying disease flare after SARS-CoV-2 vaccination among individuals with systemic autoimmune rheumatic diseases. Curr Opin Pharmacol 65:102243. https://doi.org/10.1016/j.coph.2022.102243
doi: 10.1016/j.coph.2022.102243
pubmed: 35636384
pmcid: 9058024
Edwards KM, Orenstein WA (2023) COVID19: Vaccines. Uptodate. https://www.uptodate.com/contents/covid-19-vaccines . Accessed 31 May 2023
Shiravi AA, Ardekani A, Sheikhbahaei E, Heshmat-Ghahdarijani K (2022) Cardiovascular complications of SARS-CoV-2 vaccines: an overview. Cardiol Ther 11:13–21. https://doi.org/10.1007/s40119-021-00248-0
doi: 10.1007/s40119-021-00248-0
pubmed: 34845662
Marcec R, Likic R (2022) Using Twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines. Postgrad Med J 98:544–550. https://doi.org/10.1136/postgradmedj-2021-140685
doi: 10.1136/postgradmedj-2021-140685
pubmed: 34373343
Biswas MR, Alzubaidi MS, Shah U, Abd-Alrazaq AA, Shah Z (2021) A scoping review to find out worldwide COVID-19 vaccine hesitancy and its underlying determinants. Vaccines (Basel) 9:1243. https://doi.org/10.3390/vaccines9111243
doi: 10.3390/vaccines9111243
pubmed: 34835174